Update shared on02 Sep 2025
Fair value Decreased 0.86%The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53.
What's in the News
- Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.
- The company repurchased 3,944,683 shares for $71.87 million between April 1 and July 24, 2025, completing a total buyback of 5,091,156 shares for $94.17 million under its current program.
- Healthpeak Properties was added to the Russell 1000 Value-Defensive Index.
- Healthpeak Properties was added to the Russell 1000 Defensive Index.
Valuation Changes
Summary of Valuation Changes for Healthpeak Properties
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $21.72 to $21.53.
- The Future P/E for Healthpeak Properties has fallen slightly from 97.47x to 93.91x.
- The Consensus Revenue Growth forecasts for Healthpeak Properties remained effectively unchanged, at 3.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.